Capricor (NASDAQ: $CAPR) is a biotech company focused on the development of cell & exosome-based therapeutics for treatment and prevention of serious diseases.
Joined July 2014
- Tweets 827
- Following 239
- Followers 2,581
- Likes 533
612 Photos and videos
Jun 10
Today, our CEO, Linda Marbán, presented at the Oppenheimer CNS & NeuroMuscular Summit in Miami, Florida, alongside leaders from Sarepta and Dyne during the “Advancing Duchenne: Perspectives From Industry Leaders” panel. Proud to be part of the important conversations shaping the future of Duchenne muscular dystrophy treatment and innovation.
1
2
16
561
Capricor will be participating in two investor conferences this week in Miami — the Goldman Sachs 47th Annual Global Healthcare Conference (fireside chat, June 10 at 10:00 a.m. ET) and the Oppenheimer CNS and Neuro-Muscular Summit.
To view the Goldman Sachs webcast, click here. bit.ly/3POYzHT
$CAPR #DMD #Deramiocel
1
6
381
May 29
We are pleased to welcome Michael Maurer to Capricor as our Chief Commercial Officer. With more than two decades of rare disease commercialization experience across neuromuscular disorders, neuroscience, and immunology, Michael's deep expertise bringing complex therapies to patients further strengthens our team as we prepare for the potential launch of Deramiocel for Duchenne muscular dystrophy and work toward our August 22 PDUFA date. Click here to read the announcement bit.ly/3RFEyUw $CAPR #DMD #Duchenne #Deramiocel
3
16
672
May 22
Capricor is presenting today at the CureDuchenne FUTURES Conference in Orlando, FL. Join us during the Science Main Stage Session: Preserving, Protecting, & Regenerating Muscle from 11:00 AM – 12:30 PM ET.
View the full conference agenda here: web.cvent.com/event/ee9e7402…
$CAPR #DMD #CureDuchenne #Deramiocel
1
12
931
May 14
Capricor is proud to be presenting our HOPE-3 results at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held this week in Boston (May 11–15). With over 2,000 abstracts showcasing the latest in cell and gene therapy, this is one of the premier gatherings in the industry — and we look forward to sharing our data. Click to see the full conference agenda: annualmeeting.asgct.org/prog…
#ASGCT2026 #DMD #HOPE3 $CAPR #Deramiocel
2
17
534
May 12
Capricor just reported its first quarter 2026 financial results and provided a recent corporate update. Click here to read the full release: bit.ly/4udKQcy
$CAPR #DMD #Deramiocel
3
12
576
Capricor will report its first quarter 2026 financial results and provide a recent corporate update on May 12 at 4:30 p.m. ET.
Register for the webcast to stay up to date on our progress and key developments: bit.ly/3P1v5Ww
$CAPR #Deramiocel #DMD
1
14
597
Apr 21
At the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Capricor will be presenting Phase 3 HOPE-3 results for Deramiocel in a late-breaking oral presentation later today. The presentation highlights previously reported topline data demonstrating significant functional benefits in patients with Duchenne muscular dystrophy (DMD). For more information, please click bit.ly/4cXjCAt
$CAPR #Deramiocel #DMD #AANAM #Duchenne
4
18
1,434
Mar 23
Capricor is pleased to be attending the 38th Annual Roth Conference this week in Dana Point, California. The annual conference brings together more than 400 public and private companies, along with investors, for expert-led panels and keynotes across a range of multiple sectors.
#ROTHConference $CAPR
1
9
489
Mar 12
We just reported our fourth quarter and full year 2025 financial results. Click here to read the release: bit.ly/4bKdCcP
Our quarterly conference call begins at 4:30 p.m. ET – join the webcast here: bit.ly/3NjKRLy
$CAPR #DMD #Deramiocel
1
1
19
797
Mar 12
Yesterday at #MDA2026, we presented late-breaking data from the Phase 3 HOPE-3 trial highlighting Deramiocel’s potential impact on functional outcomes in Duchenne muscular dystrophy.
Read the full release: bit.ly/3NfTTcE
$CAPR #DMD #Deramiocel
1
1
16
1,732
Mar 10
We’re pleased to be attending the 2026 MDA Conference this week in Orlando, Florida. This important meeting brings together clinicians, researchers and patient advocates to discuss the latest developments in Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.
Capricor will be featured in the late-breaking presentation on March 11 and will also be at Booth #407 during the meeting.
If you’re attending, please stop by and say hello.
#MDA2026 $CAPR #MuscularDystrophy #DMD #Deramiocel
3
1
26
585
Mar 10
Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular dystrophy and set a PDUFA target action date of August 22, 2026.
Click here to read the announcement: bit.ly/4bz2qk2
#DMD #Deramiocel $CAPR
3
8
42
3,850
Feb 28
February 28 is Rare Disease Day 💜
Today, we stand with the more than 300 million people worldwide living with a rare disease — including those affected by Duchenne muscular dystrophy (DMD). At Capricor, our mission is clear: advance innovative therapies and work with urgency to bring new options to patients and families who need them most.
Today and every day, we remain focused on transforming innovation into hope.
#RareDiseaseDay #DMD #RareButNotAlone $CAPR
7
31
589
Feb 24
We are pleased to share that Capricor has been selected for a late-breaking oral presentation at the 2026 MDA Clinical & Scientific Conference featuring our Phase 3 HOPE-3 results, alongside the submission of the HOPE-3 clinical study report to the U.S. FDA in support of our ongoing BLA review.
To read the full announcement, click here: bit.ly/4cLtDB9
$CAPR #DMD #MDAconference #MuscularDystrophy #HopeForDMD
1
2
15
460
Jan 20
We are pleased to provide a regulatory update on Deramiocel following FDA review of the HOPE-3 topline data. The FDA has requested the HOPE-3 clinical study report, an expected step as the BLA review progresses.
Click to read the release: bit.ly/4b8MiWU
$CAPR #DMD #Dearamiocel
1
6
24
1,497
Jan 14
Our CEO, Linda Marbán, joined Amy Brown on @BiotechTV at the JPM Healthcare Conference to reflect on a meaningful year for our Duchenne muscular dystrophy program. The conversation highlights key milestones for Deramiocel, including the Phase 3 HOPE-3 readout as well as next steps in the regulatory review and what this progress could mean for individuals and families in the DMD community.
Watch the full interview here: biotechtv.com/post/capricor-…
$CAPR #JPM2026 #JPM26 #JPMHealthcare #Deramiocel #DMD
2
10
889